ReviewFuture microbiology2011
Development of new vaccines and drugs for TB: limitations and potential strategic errors.
Review in Future microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Attenuated but immunostimulatory Mycobacterium tuberculosis variant bovis strain Ravenel shows variation in T cell epitopes.Scientific reports · 2023Article
- Evolution of Drug-ResistantFrontiers in microbiology · 2021Review
- Identification and Characterization of Two Defensins from Capsicum annuum Fruits that Exhibit Antimicrobial Activity.Probiotics and antimicrobial proteins · 2020Article
- Article
- GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.Clinical and vaccine immunology : CVI · 2017Article
- A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model.Scientific reports · 2017Article
- Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2016Review
- Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1.Scientific reports · 2016Article
- Article
- Tuberculosis vaccine types and timings.Clinical and vaccine immunology : CVI · 2015Review
- The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis.PloS one · 2015Article
- Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.Clinical and vaccine immunology : CVI · 2015Article
- Whole genome response in guinea pigs infected with the high virulence strain Mycobacterium tuberculosis TT372.Tuberculosis (Edinburgh, Scotland) · 2014Article
- Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2014Article
- A new unifying theory of the pathogenesis of tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2014Article
- Review
- The expression of ABC efflux pump, Rv1217c-Rv1218c, and its association with multidrug resistance of Mycobacterium tuberculosis in China.Current microbiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The concomitant HIV and TB epidemics pose an enormous threat to humanity. After invading the host Mycobacterium tuberculosis initially behaves as an intracellular pathogen, which elicits the emergence of acquired specific resistance in the form of a T-helper-1 T-cell response, and involves the secretion of a myriad of cytokines and chemokines to drive protective immunity and granuloma formation. However, after that, a second phase of the disease process involves survival of bacilli in an extracellular state that is still poorly understood. This article briefly reviews the various strategies currently being used to improve both vaccination and drug therapy of TB, and attempts to make the argument that current viewpoints that dominate [both the field and the current literature] may be seriously flawed. This includes both the choice of new vaccine and drug candidates, and also the ways these are being tested in animal models, which in the opinion of the author run the risk of driving the field backwards rather than forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.